Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 95Active not recruiting 73Completed 25Not yet recruiting 19Terminated 6Withdrawn 3Enrolling by invitation 3Suspended 1Available 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Neoplasms 12Prostatic Neoplasms 8Recurrence 4Lung Neoplasms 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma, B-Cell 3Lymphoma 3Colorectal Neoplasms 3Cancer Pain 3Uterine Cervical Neoplasms 2Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pain 2Ovarian Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2

Interventions

tazemetostat 1tafasitamab 1etoposide phosphate 1Vincristine 1Prednisone 1Prednisolone 1Melphalan 1Lenalidomide 1Etoposide 1Doxorubicin 1Cytarabine 1Cyclophosphamide 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma × 90 days × Clear all
NCT07453446 2026-05-06

Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Phase 1 Withdrawn
Lymphoid

Lymphoma, Recurrence

NCT07030699 2026-04-07

ECLAT

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Lymphoid

Lymphoma

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡